Skip to content

Replimune Group REPL Accounts Payable

Accounts Payable at other companies

Amgen logo
AmgenAMGN
$2.94B+22.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.03B+45.6%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$8.76M-1.5%
Immunome logo
ImmunomeIMNM
$5.53M-39.4%
CG Oncology logo
CG OncologyCGON
$8.24M+22.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$2.16M-4.4%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's accounts payable?
Replimune Group (REPL) reported accounts payable of $5.65M in Q4 2025.
How has Replimune Group's accounts payable changed year-over-year?
Replimune Group's accounts payable decreased by 21.4% year-over-year, from $7.19M to $5.65M.
What is the long-term trend for Replimune Group's accounts payable?
Over 4 years (2021 to 2025), Replimune Group's accounts payable has grown at a 51.7% compound annual growth rate (CAGR), from $2.36M to $12.46M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.